STOCKHOLDERS' EQUITY (Tables)

9 Months Ended

Nov. 30, 2023

Equity [Abstract]

Schedule of Stock-based Compensation Expense

Stock-based compensation expense is included in the following captions of the condensed consolidated statements of comprehensive loss (in thousands):

	Three Months Ended				Nine Months Ended
	November 30,				November 30,
	2023		2022		2023		2022
Cost of revenues	$	26	$	3	$	91	$	88
Research and development		257		528		941		1,964
Selling and marketing		460		737		1,607		2,046
General and administrative		824		762		2,830		4,088
	$	1,567	$	2,030	$	5,469	$	8,186

Summary of Stock Option Activity

Changes in our outstanding stock options during the nine months ended November 30, 2023 were as follows (options in thousands):

	Number of Options			Weighted Average Exercise Price		Weighted average remaining contractual life (years)		Aggregate intrinsic value
Outstanding at February 28, 2023		506		$	16.02		4.0
Granted		—			—
Exercised		—			—
Forfeited or expired		(506	)		16.02
Outstanding at November 30, 2023		-		$	-			$	-
Exercisable at November 30, 2023		-		$	-			$	-

Summary of Restricted Stock Shares (RSU's), and Performance Stock Units (PSU's) Activity

Changes in our outstanding restricted stock shares, performance stock units (“PSUs”) and restricted stock units (“RSUs”) during the nine months ended November 30, 2023 were as follows (restricted shares, PSUs and RSUs in thousands):

	Number of Restricted Shares, PSUs and RSUs			Weighted Average Grant Date Fair Value		Shares Retained to Cover Statutory Minimum Withholding Taxes
Outstanding at February 28, 2023		3,506		$	6.75
Granted		3,109			0.83
Vested		(1,149	)		7.16		155
Forfeited		(1,284	)		4.50
Outstanding at November 30, 2023		4,182		$	2.41